| [1] |
Ebata T, Kamiya J, Nishio H, et al. The concept of perihilar cholangiocarcinoma is valid[J]. Br J Surg, 2009, 96(8):926-934.
|
| [2] |
Aoba T, Ebata T, Yokoyama Y, et al. Assessment of nodal status for perihilar cholangiocarcinoma: location, number, or ratio of involved nodes[J]. Ann Surg, 2013, 257(4):718-725.
|
| [3] |
Nagino M, Ebata T, Yokoyama Y, et al. Evolution of surgical treatment for perihilar cholangiocarcinoma: a single-center 34-year review of 574 consecutive resections[J]. Ann Surg, 2013, 258(1):129-140.
|
| [4] |
Buettner S, Margonis GA, Kim Y, et al. Conditional probability of long-term survival after resection of hilar cholangiocarcinoma[J]. HPB, 2016, 18(6):510-517.
|
| [5] |
Burke EC, Jarnagin WR, Hochwald SN, et al. Hilar cholangiocarcinoma: patterns of spread, the importance of hepatic resection for curative operation, and a presurgical clinical staging system[J]. Ann Surg, 1998, 228(3):385-394.
|
| [6] |
Jarnagin WR, Fong Y, DeMatteo RP, et al. Staging, resectability, and outcome in 225 patients with hilar cholangiocarcinoma[J]. Ann Surg, 2001, 34(4):507-517.
|
| [7] |
Deoliveira ML, Schulick RD, Nimura Y, et al. New staging system and a registry for perihilar cholangiocarcinoma[J]. Hepatology, 2011, 53(4):1363-1371.
|
| [8] |
Sasaki R, Murata S, Oda T, et al. Evaluation of UICC-TNM and JSBS staging systems for surgical patients with extrahepatic cholangiocarcinoma[J]. Langenbecks Arch Surg, 2010, 395(6):615-623.
|
| [9] |
Gazzaniga GM, Faggioni A, Filauro M. Surgical treatment of proximal bile duct tumors[J]. Int Surg, 1985, 70(1):45-48.
|
| [10] |
Jarnagin W, Winston C. Hilar cholangiocarcinoma: diagnosis and staging[J]. HPB, 2005, (4):244-251.
|
| [11] |
Hrudka J, Oliverius M, Gürlich R. Pathology of cholangiocellular carcinoma[J]. Cas Lek Cesk, 2019, 158(2):57-63.
|
| [12] |
唐浩文, 蒙轩, 吕文平, 等. 胆管癌诊断及预后相关分子标记物研究进展[J]. 解放军医学院学报, 2018, 39(2):165-167.
|
| [13] |
Rizvi S, Gores GJ. Emerging molecular therapeutic targets for cholangiocarcinoma[J]. J Hepatol, 2017, 67(3):632-644.
|
| [14] |
Labib PL, Goodchild G, Pereira SP. Molecular pathogenesis of cholangiocarcinoma[J]. BMC Cancer, 2019, 19(1):185.
|
| [15] |
Endo I, Matsuyama R, Mori R, et al. Imaging and surgical planning for perihilar cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci, 2014, 21(8):525-532.
|
| [16] |
Song SC, Choi DW, Kow AW, et al. Surgical outcomes of 230 resected hilar cholangiocarcinoma in a single centre[J]. ANZ J Surg, 2013, 83(4):268-274.
|
| [17] |
Hakeem AR, Marangoni G, Chapman SJ, et al. Does the extent of lymphadenectomy, number of lymph nodes, positive lymph node ratio and neutrophil-lymphocyte ratio impact surgical outcome of perihilar cholangiocarcinoma?[J]. Eur J Gastroenterol Hepatol, 2014, 26(9):1047-1054.
|
| [18] |
Kitagawa Y, Nagino M, Kamiya J, et al. Lymph node metastasis from hilar cholangiocarcinoma: audit of 110 patients who underwent regional and paraaortic node dissection[J]. Ann Surg, 2001, 233(3):385-392.
|
| [19] |
Tsukahara T, Ebata T, Shimoyama Y, et al. Residual carcinoma in situ at the ductal stump has a negative survival effect: an analysis of early-stage cholangiocarcinomas[J]. Ann Surg, 2017, 266(1):126-132.
|
| [20] |
Endo I, House MG, Klimstra DS, et al. Clinical significance of intraoperative bile duct margin assessment for hilar cholangiocarcinoma[J]. Ann Surg Oncol, 2008, 15(8):2104-2112.
|
| [21] |
Ribero D, Amisano M, Lo TR, et al. Additional resection of an intraoperative margin-positive proximal bile duct improves survival in patients with hilar cholangiocarcinoma[J]. Ann Surg, 2011, 254(5): 776-781.
|
| [22] |
Otsuka S, Ebata T, Yokoyama Y, et al. Clinical value of additional resection of a margin-positive distal bile duct in perihilar cholangiocarcinoma[J]. Br J Surg, 2019, 106(6):774-782.
|
| [23] |
Nagino M. Cutting edge of an aggressive surgical approach for perihilar cholangiocarcinoma[J]. Updates Surg, 2013, 65(2):81-83.
|
| [24] |
Nagino M, Nimura Y, Nishio H, et al. Hepatectomy with simultaneous resection of the portal vein and hepatic artery for advanced perihilar cholangiocarcinoma: an audit of 50 consecutive cases[J]. Ann Surg, 2010, 252(1):115-123.
|
| [25] |
Matsuyama R, Mori R, Ota Y, et al. Significance of vascular resection and reconstruction in surgery for hilar cholangiocarcinoma: with special reference to hepatic arterial resection and reconstruction[J]. Ann Surg Oncol, 2016, 23(Suppl 4):475-484.
|
| [26] |
Schimizzi GV, Jin LX, Davidson JT 4th, et al. Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium[J]. HPB, 2018, 20(4):332-339.
|
| [27] |
Nimura Y, Kamiya J, Kondo S, et al. Aggressive preoperative management and extended surgery for hilar cholangiocarcinoma: Nagoya experience[J]. J Hepatobiliary Pancreat Surg, 2000, 7(2):155-162.
|
| [28] |
Horgan AM, Amir E, Walter T, et al. Adjuvant therapy in the treatment of biliary tract cancer: a systematic review and meta-analysis[J]. J Clin Oncol, 2012, 30(16):1934-1940.
|
| [29] |
McNamara MG, Walter T, Horgan AM, et al. Outcome of adjuvant therapy in biliary tract cancers[J]. Am J Clin Oncol, 2015, 38(4):382-387.
|
| [30] |
Lidsky ME, Jarnagin WR. Surgical management of hilar cholangiocarcinoma at Memorial Sloan Kettering Cancer Center[J]. Ann Gastroenterol Surg, 2018, 2(4):304-312.
|
| [31] |
Malka D, Cervera P, Foulon S, et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial[J]. Lancet Oncol, 2014, 15(8):819-828.
|
| [32] |
Moehler M, Maderer A, Ehrlich A, et al. Safety and efficacy of afatinib as add-on to standard therapy of gemcitabine/cisplatin in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, phase I trial with an extensive biomarker program[J]. BMC Cancer, 2019, 19(1):55.
|
| [33] |
Ueno M, Ikeda M, Morizane C, et al. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study[J]. Lancet Gastroenterol Hepatol, 2019, 4(8):611-621.
|
| [34] |
Washington MK, Berlin J, Branton PA, et al. Protocol for the examination of specimens from patients with carcinoma of the perihilar bile ducts[J]. Arch Pathol Lab Med, 2010, 134(4):e19-24.
|
| [35] |
耿智敏, 巩鹏, 宋天强, 等. 多学科团队开展胆道肿瘤病理学取材及报告规范化的意义[J]. 中华消化外科杂志, 2017, 16(1):47-52.
|